Chairs: Chris Cannon (USA), Sam Dagogo-Jack (USA)
Faculty: David Cherney (CAN), Ildiko Lingvay (USA), Francesco Cosentino (SWE)

14:30 – 14:35Opening RemarksChairs (USA)
14:35 – 14:45Ertugliflozin and VERTIS CV – New Data Expanding Our Understanding for the Treatment of Patients With Type 2 Diabetes and Cardiovascular DiseaseSam Dagogo-Jack (USA)
14:45 – 14:55Recent Data on the Efficacy and Safety of Ertugliflozin Using Insulin in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular DiseaseIldiko Lingvay (USA)
14:55 – 15:05The Latest VERTIS CV Heart Failure Results – Adding to Our Clinical Understanding From a Cardiologist’s ViewFrancesco Cosentino (SWE)
15:05 – 15:15New VERTIS CV Kidney Protection Results – Adding to Our Clinical  Understanding From a Nephrologist’s ViewDavid Cherney (CAN)
15:15 – 15:28What Does It All Mean For Our Patients? A Cross-Specialty Faculty Roundtable DiscussionFaculty
15:28 – 15:30Closing RemarksChairs (USA)

Program Chair’s Introduction and Welcome
Applying Sensor‐Based Technology to Optimize Blood Glucose Time-in-Range (TIR) and Health Metrics Across the Comprehensive Spectrum of Diabetes Care: Establishing a New, Guideline- and Evidence-Based Standard of Care for Persons with Diabetes

Session 1
Applying Sensor-Based Glucose Monitoring and Telemedicine to Optimize Real World Impact and Diabetes Management in the Age of Covid-19 and Beyond—What Have the Studies Taught Us? How Do We Apply Them to Diabetes Practice Now?

Session 2
A Practical Roadmap for Using Registry Data and Trial-Based Evidence to Guide Use of Sensor‐Based, Glucose Monitoring: Focus on Results from National Diabetes Registries (NDRs) to Optimize Multi-Dose Insulin (MDI) Therapy in Persons with Diabetes

Session 3
Translating Guidelines and Meta‐Analysis Trials to Guide Practical Aspects of Diabetes Care: Using Sensor-Based Glucose Monitoring to Improve Time in Range (TIR), GMI and AGP for Persons with Diabetes on Non-Insulin Regimens

Program Chair’s Summary and Vision Statement
The Foundational Role of Sensor‐Based Glucose Monitoring Technology — How Should Clinicians and Patients Collaborate to Maximize Blood Glucose Time in Range and Improve Safety and Health Outcomes in Persons with Diabetes?

Chair: Jiten Vora (UK) Co-Chair: Nayyar Iqbal (AstraZeneca)
14:30 – 14:35 Welcome Elisabeth Björk (AstraZeneca) Jiten Vora (UK) Nayyar Iqbal (AstraZeneca)
14:35 – 14:50 Role of water conservation and metabolism in SGLT2 inhibitor mediated organ protection Jens Marc Titze (SGP)
14:50 – 15:10 Cracking the code in CKD: Mechanisms of renoprotection Hiddo Heerspink (NLD)
15:10 – 15:30 SGLT2 inhibitors in HF: Piecing together the puzzle of preserved ejection fraction Sanjiv Shah (USA)
15:30 – 15:40 Panel discussion All faculty
15:40 – 15:55 State of art lecture:  NASH, disease burden and new opportunities – Emerging new modalities to manage NASH Arun Sanyal (USA)
15:55 – 16:00 Closing remarks Regina Fritsche-Danielson (AstraZeneca) Jiten Vora (UK)

14:30 – 14:35


Chair: Tina Vilsbøll (DNK)

14:35 – 14:47

Should we have a more holistic treatment approach to improve healthy lifespan in people living with T2D?

Vanita Aroda (USA)

14:47 – 15:10

Panel discussion

Vanita Aroda (USA)
Melanie Davies (UK)
John Buse (USA)
Nikolaus Marx (GER)

15:10 – 15:20

Treatment intensification in T2D with high-dose semaglutide: SUSTAIN FORTE

Juan Pablo Frias (USA)

15:20 – 15:25

Questions from the audience


15:25 – 15:27

Welcome back

Chair: Tina Vilsbøll (DNK)

15:27 – 15:35

The potential of semaglutide 2.4 mg for weight management

Rachel Batterham (UK)

15:35 – 15:45

Changing the paradigm in obesity care: the STEP 1–4 data

Melanie Davies (UK)

15:45 – 15:55

The clinical impact of double-digit weight loss

John Wilding (UK)

15:55 – 16:08

Questions from the audience


16:08 – 16:10

Thanks and wrap-up

Chair: Tina Vilsbøll (DNK)

16:30 – 16:35


Chair: Tina Vilsbøll (DNK)

16:35 – 16:45

Insulin innovations – the past: journey so far

Andreas Liebl (GER)

16:45 – 16:55

Insulin innovations – the present: current scenario

Lena Landstedt-Hallin (SWE)

16:55 – 17:05

Patient case study

Andreas Liebl (GER)
Lena Landstedt-Hallin (SWE)

17:05 – 17:20

Insulin innovations – the future: roadmap to the future

Ronald Goldenberg (CAN)

17:20 – 17:28

Panel discussion


17:28 – 17:30

Thanks and wrap-up

Chair: Tina Vilsbøll (DNK)

19:00 – 19:05


Chair: Tina Vilsbøll (DNK)

19:05 – 19:30

Highlights and learnings: current diabetes and obesity management and future opportunities


09:15 – 09:20

Overview of oral semaglutide and PIONEER trials

Filip K Knop (DNK)

09:20 – 09:30

Case scenarios based on clinical evidence

Filip K Knop (DNK)
Vanita Aroda (USA)

09:30 – 09:35

Patient-centric practicalities

Vanita Aroda (USA)

09:35 – 09:45

A patient-centered approach with oral semaglutide

Panel discussion and Q&A (live)


17:40 – 17:45

The case challenge
Teaming up to tackle cardiorenal risk in diabetes

Melanie Davies (UK)

17:45 – 17:55

Defining treatment goals: SGLT2i, implications from clinical trials and guidelines

Nikolaus Marx (GER)

17:55 – 18:05

Practical Challenges: SGLT2i in the spectrum of diabetes, CVD & CKD: Who and how to manage?

Melanie Davies (UK)

18:05 – 18:10

Discussion How to overcome clinical inertia?

Nikolaus Marx (GER)
Melanie Davies (UK)


Educational objectives

  • To summarise the epidemiology and pathophysiology of patients with diabetes, CVD and CKD
  • To discuss the role of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiorenal risk
  • To address the remaining questions on the role of SGLT2 inhibition in the management of patients with diabetes and cardiorenal complications
  • To provide an expert perspective on the clinical management of patients with type 2 diabetes, CKD and CV

17:40 – 17:55

obesity, weight loss and CV risk

Kim Connelly (CAN)

17:55 – 18:10

STEPping forward:
cardiovascular risk factors in patients with overweight or obesity

Ildiko Lingvay (USA)

18:10 – 18:25

STEPping into the future:
managing cardiovascular outcomes in people with overweight or obesity

Subodh Verma (CAN)

18:25 – 18:40

Live Q&A

Chaired by Kim Connelly (CAN)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
17:40 – 18:00Optimizing outcomes with the MiniMedTM 780G system: evidence from real-world usageOhad Cohen
18:00 – 18:20Best practices with the MiniMedTM 780G System Tadej Battelino
18:20 – 18:40Combining InPen and CGM to Improve Glycemic Outcomes in MDI UsersRobert Vigersky
18:40 – 18:55Next Steps in the Advancement of technologies for the treatment of diabetesAli Dianati
18:55 – 19:10Questions & AnswersOhad Cohen

Chair: Rolf Hinzmann (Roche Diabetes Care, GER)

17:40 – 17:45

17:45 – 18:15Integrated Personalised Diabetes Management drives improved
patient-reported outcomes
Kamlesh Khunti (UK)
18:15 – 18:35Decision support solutions using Artificial Intelligence enable earlier detection of CKDNavdeep Tangri (CAN)
18:35 – 18:55Innovative therapies and future integrated solutions can enhance management of diabetic eye diseasePraveen Patel (UK)
18:55 – 19:10Discussion and Closing 


  • Associate Professor Neale Cohen FRACP
    Head Clinical Diabetes
    Baker Heart and Diabetes Institute
  • Dr Martin de Bock FRACP PhD
    Paediatric Endocrinologist
    University of Otago and Canterbury District Health Board

Supported by an unrestricted educational grant from Gan & Lee

Chairs: Tina Vilsbøll (DNK), Lutz Heinemann (GER)

19:30 – 19:33IntroductionTina Vilsbøll (DNK)
19:33 – 19:43Biosimilar Insulin Manufacturing: Why the process IS the product?Lutz Heinemann (GER)
19:43 – 19:53Why do patient and HCP perceptions about biosimilar insulin matter?Philip Home (UK)
19:53 – 20:00Discussion and closureAll


18:30 – 18:32


Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:32 – 18:35

A retrospective look:
100 years since insulin was discovered

Simon Heller (UK)

18:35 – 18:47

Once-weekly basal insulins:
From innovation to RCTs

Athena Philis-Tsimikas (USA)

18:47 – 18:53

Patient-centric care:
How once-weekly options may help get patients to target

Simon Heller (UK)

18:53 – 18:58

Questions from the audience

Facilitated by:

Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:58 – 19:00


Athena Philis-Tsimikas (USA)
Simon Heller (UK)


  • John Buse (chair, USA)
  • Kate Stevens (UK)
  • Nikolaus Marx (GER)
  • Naresh Kanumilli (UK)

Four experts in primary care, endocrinology, cardiology and nephrology will come together to discuss a patient-centred and evidence-based approach to care in T2D after metformin, offering their clinical perspectives on the optimal and multifactorial management of an evolving patient case

Chairs: Ofri Mosenzon (ISR), Rich Pratley (USA)
Faculty: Chris Cannon (USA), David Cherney (CAN)

18:30 – 18:33Opening RemarksChairs (ISR, USA)
18:33 – 18:41Highlighting the Patient with Diabetes and Cardiometabolic DiseaseRich Pratley (USA)
18:41 – 18:49Answering Unmet Needs – Clinical Understanding of Recent Heart Failure Data for Patients with Diabetes and Cardiovascular DiseaseChris Cannon (USA)
18:49 – 18:57Adding to the Clinical Understanding for Patients with Diabetes and Cardio-renal DiseaseDavid Cherney (CAN)
18:57 – 19:27 A Cross-Specialty Faculty Roundtable on Meeting the Needs of Patients with Diabetes and Established Cardiometabolic Disease: Are SGLT2is Best Utilized as a Cardiovascular Drug? A Kidney Drug? A Glycemic Lowering Agent? Or All of the Above?Faculty
19:27 – 19:30Closing RemarksChairs (ISR, USA)

Supported by an unrestricted educational grant from Amarin Pharma, Inc.

18:30 – 18:35

Welcome, Introductions, Program Overview

Dirk Müller-Wieland

18:35 – 18:55

New Clinical Evidence of Omega-3 Fatty Acids on ASCVD Event Reduction

Dirk Müller-Wieland

18:55 – 19:15

Real-world Clinical Implications on Reducing ASCVD Events

Handrean Soran

19: 15 – 19:30

Panel Discussion and Q&A

Handrean Soran

Dirk Müller-Wieland

Closing Comments

Dirk Müller-Wieland
Handrean Soran


Learning Objectives

At the conclusion of this activity, learners should be better able to:

  • Describe the spectrum of large-scale outcomes trials of omega-3 fatty acids on ASCVD events.
  • Appreciate the differences between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Chair: Matthias Laudes
Speakers: Francesco Giorgino, Vaia Lambadiari

Welcome and introductionMatthias Laudes
Diagnosis of severe insulin resistance and atypical diabetes and when to suspect lipodystrophyFrancesco Giorgino
The management of lipodystrophy: clinical challenges and treatment opportunitiesVaia Lambadiari
Q&A, conclusionsMatthias Laudes


09:15 – 09:35

How and why to identify high-risk patients: lessons from the clinic

Elmar Jaeckel (GER)
Lise Lotte Gluud (DNK)

09:35 – 09:45

The future of NASH: the importance of interdisciplinary collaboration (interactive Q&A)

Elmar Jaeckel (GER)
Lise Lotte Gluud (DNK)

Faculty: David Cherney (CAN), Kim Connelly (CAN), Sam Dagogo-Jack (USA)

18:15 – 18:20Opening RemarksSam Dagogo-Jack (USA)
18:20 – 18:43Cross-talk between the Heart, Kidneys & the Endocrine System – Understanding for Type 2 Diabetes and Cardiorenal DiseaseDavid Cherney (CAN)
Kim Connelly (CAN)
Sam Dagogo-Jack (USA)
18:43 – 18:45Closing RemarksSam Dagogo-Jack (USA)

We invite you to attend our educational program on the occasion of the virtual EASD Annual Meeting 2021 to engage in a collaborative discussion with our panelists, program faculty, and your colleagues on optimizing multidisciplinary care for your complex cardiometabolic patients.

Supported by an independent educational grant from Novo Nordisk


Naveed Sattar (UK)

Mark Petrie (UK)
Kamlesh Khunti (UK)

18:15 – 18:30

The Endocrinologist in the Lead

The Right Drug for the Right Patient at the Right Time

Naveed Sattar (UK)


18:30 – 18:45

The Cardiologist in the Lead

Primary and Secondary Cardiovascular Protection

Mark Petrie (UK)

18:45 – 19:00

The Primay Care Physician in the Lead

Implementing Proactive Diabetes Care across the Stages

Kamlesh Khunti (UK)

19:00 – 19:15

Panel Discussion and Q & A

All Faculty 




20:00 – 20:05

Welcome and IntroductionsBo Ahrén (SWE)
20:05 – 20:40Health risks associated with elevated postprandial glucose or increased glycaemic variability 

Louis Monnier (FRA)

20:40 – 21:15Nonpharmacological interventions for postprandial glucose management

Bo Ahrén (SWE)

21:15 – 21:30Live Q & A and close Interactive discussion with speakers


Supported by an independent educational grant from Lilly

08:15 – 08.25

Better Metabolic Health with Incretin-based Therapies – Achievements and Ambitions

08:25 – 08:40

The Power of novel dual GIP/GLP-1 Receptor Agonists 

08:40 – 09:00

The Clinical Evidence for GIP/GLP-1 Receptor Agonists – Assessing the Emerging Profile

09:00 – 09:15

Panel Discussion and Q & A




17:40 – 17:43


Adie Viljoen (UK)

17:43 – 17:51

Early treatment: what are the benefits of early initiation of GLP-1RAs?  

Tina Vilsbøll (DNK)
Juris Meier (GER)

17:51 – 18:01

Discussion session 1

Tina Vilsbøll (DNK)
Juris Meier (GER)

18:01 – 18:09

Spotlight on: type 2 diabetes management for those with renal impairment

Tina Vilsbøll (DNK)
Peter Rossing (DNK)

18:09 – 18:19

Discussion and Q&A

Tina Vilsbøll (DNK)
Peter Rossing (DNK)

18:19 – 18:27

Spotlight on: glycaemic management in individuals with T2D and CVD

Matt Cavender (USA)
David Strain (UK)

18:27 – 18:37

Discussion session 2

Matt Cavender (USA)
David Strain (UK)

18:37 – 18:40

A look at what is up and coming

Adie Viljoen (UK)